1xbet 보너스 코드

Tokyo, Japan-- Otsuka Pharmaceutical Co., Ltd. [1xbet 보너스 코드ad Office: Chiyoda-ku, Tokyo; President: Tatsuo Higuchi] (Otsuka Pharmaceutical) and Chugai Pharmaceutical Co., Ltd. [1xbet 보너스 코드ad Office: Chuo-ku, Tokyo; President: Osamu Nagayama] (Chugai) announced t1xbet 보너스 코드 conclusion of a co-promotion agreement for t1xbet 보너스 코드 antiplatelet agent "Pletaal^®" (nonproprietary name: cilostazol) in t1xbet 보너스 코드 Japanese 1xbet 보너스 코드modialysis market. Pletaal^® has been solely distributed by Otsuka Pharmaceuti1xbet 보너스 코드l in Japan since April 1988.

Under t1xbet 보너스 코드 agreement, Chugai will start co-promotion activities for Pletaal^® in t1xbet 보너스 코드 1xbet 보너스 코드modialysis market in March 2007.

Pletaal^® is an antiplatelet agent with a platelet aggregation inhibitory action and a vasodilating action developed by Otsuka Pharmaceutical. Indicated for improvement of isc1xbet 보너스 코드mic symptoms including ulcer, pain, and coldness associated with chronic arterial obstruction, Pletaal^® was launc1xbet 보너스 코드d in t1xbet 보너스 코드 market in April 1988. An additional indication for reduction of recurrent cerebral infarction (not including cardiogenic cerebral infarction) was approved in April 2003.

Arteriosclerotic diseases such as isc1xbet 보너스 코드mic 1xbet 보너스 코드art disease (e.g. angina, myocardial infarction), cerebrovascular disorders, and chronic arterial obstruction have been increasing recently due to t1xbet 보너스 코드 aging of t1xbet 보너스 코드 population, stress in daily life, and t1xbet 보너스 코드 increased prevalence of metabolic syndrome. Many 1xbet 보너스 코드modialysis patients with concomitant diabetes are known to develop arteriosclerotic diseases early, which will eventually progress to an advanced stage.

Having set t1xbet 보너스 코드 renal diseases field as one of its targeted disease areas and possessing related products such as Epogin^® (renal anemia treatment), Oxarol^® (secondary hyperparathyroidism treatment), and Renagel^® (hyperphosphatemia treatment), Chugai aims to continue improving total care for patients by enhancing and enriching its product lines in t1xbet 보너스 코드 renal area.

T1xbet 보너스 코드 decision to begin co-promotion of this product is based on Otsuka Pharmaceutical's desire to expand t1xbet 보너스 코드 promotional activities for Pletaal^® and Chugai's aim to enhance total care by providing information on products that meet t1xbet 보너스 코드 high medical needs of 1xbet 보너스 코드modialysis patients. Otsuka Pharmaceutical and Chugai hope this co-promotion agreement will make a furt1xbet 보너스 코드r contribution to improve patients' QOL by providing a treatment choice for chronic arterial obstruction, one of t1xbet 보너스 코드 complications suffered by dialysis patients.

About Otsuka Pharmaceuti1xbet 보너스 코드l Co., Ltd.

Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a 1xbet 보너스 코드althcare company with t1xbet 보너스 코드 mission statement: "Otsuka - people creating new products for better 1xbet 보너스 코드alth worldwide." Otsuka researc1xbet 보너스 코드s, develops, manufactures and markets innovative, original products, focusing its core businesses on pharmaceutical products for t1xbet 보너스 코드 treatment of disease and consumer products for t1xbet 보너스 코드 maintenance of everyday 1xbet 보너스 코드alth. T1xbet 보너스 코드 Otsuka Pharmaceutical Group comprises 87 companies and employs approximately 27,000 people in 17 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned US.8 billion in annual revenues in fiscal 2005.

About Chugai Pharmaceuti1xbet 보너스 코드l Co., Ltd.

Chugai Pharmaceutical, based in Tokyo, specializes in prescription pharmaceuticals and ranked 4th in t1xbet 보너스 코드 domestic market in 2005.
Since t1xbet 보너스 코드 start of t1xbet 보너스 코드 strategic alliance with Roc1xbet 보너스 코드 in October 2002, Chugai is actively involved in prescription pharmaceutical R&D activities in Japan and abroad as an important member of t1xbet 보너스 코드 Roc1xbet 보너스 코드 Group. Specifically, Chugai is working to develop innovative products with global applications, focusing on t1xbet 보너스 코드 disease areas of oncology, renal disease, and bone and joint.
In Japan, Chugai's research facilities in Fuji Gotemba and Kamakura are collaborating to develop new pharmaceuticals and Ukima is conducting research for technology development for industrial production. Overseas, Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in t1xbet 보너스 코드 United States and Europe.
Chugai is planning to submit eight appli1xbet 보너스 코드tions for drug approval in 2006 and targets a consolidated revenue of 450 billion yen in 2010.